Influence of fatty acid ethanolamides and Δ9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells

European Journal of Pharmacology

Volumn 330, Issue 2-3, 1997, Pages 231-240

  Berdyshev, Evguenii V ^b   Boichot, Elisabeth ^a   Germain, Noëlla ^a   Allain, Nathalie ^a   Anger, Jean Pierre ^a   Lagente, Vincent ^a  

^a INSERM   (France)

^b INSTITUTE OF MARINE BIOLOGY   (Russian Federation)

Author keywords

Anandamide; Cannabinoid receptors; Cytokines; Immune response; Mononuclear cells; Palmitoylethanolamide; Tetrahydrocannabinol

Indexed keywords

ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID RECEPTOR; FATTY ACID DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PALMIDROL; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL;

ARACHIDONIC ACID; ARACHIDONIC ACIDS; CYTOKINES; HUMANS; LEUKOCYTES, MONONUCLEAR; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; SECRETORY RATE; TETRAHYDROCANNABINOL;

EID: 0030751182     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01007-8     Document Type: Article

References (57)

1. Aloe L., Leon A., Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behavior. Agents Actions. 39:1993;C145-C147.
2. Ambrosini A., Bertoli E., Mariani P., Tanfani F., Wozniak M., Zolese G. N-acylethanolamines as membrane topological stress compromising agents. Biochim. Biophys. Acta. 1148:1993;351-355.
3. Bayewitch M., Avidorreiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor-adenylate cyclase inhibition and g protein coupling. FEBS Lett. 375:1995;143-147.
4. Berdyshev E.V., Boichot E., Lagente V. Anandamide - A new look on fatty acid ethanolamides. J. Lipid Mediators Cell Signal. 15:1996;49-67.
5. Blanchard D.K., Newton C., Klein T.W., Stewart W.E. II, Friedman H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int. J. Immunopharmacol. 8:1986;819-824.
6. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Lefur G., Casellas P. Cannabinoid-receptor expression in human-leukocytes. Eur. J. Biochem. 214:1993;173-180.
7. Burstein S., Budrow J., Debatis M., Hunter S.A., Subramanian A. Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48:1994;1253-1264.
8. 9-tetrahydrocannabinol decreases serum alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc. Soc. Exp. Biol. Med. 181:1986;305-311.
9. Cabral G.A., Toney D.M., Fischer-Stenger K., Harrison M.P., Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci. 56:1995;2065-2072.
10. Coffey R.G., Yamamoto Y., Snella E., Pross S. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem. Pharmacol. 52:1996;743-751.
11. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in-vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
12. Daftarian P.M., Kumar A., Kryworuchko M., Diazmitoma F. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J. Immunol. 157:1996;12-20.
13. Derocq J.-M., Ségui M., Marchand J., Le Fur G., Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett. 369:1995;177-182.
14. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that bids to the cannabinoid receptor. Science. 258:1992;1946-1949.
15. Diaz S., Specter S., Vanderhoek J.Y., Coffey R.G. The effect of delta-9-tetrahydrocannabinol on arachidonic acid metabolism in human peripheral blood mononuclear cells. J. Pharmacol. Exp. Ther. 268:1994;1289-1296.
16. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
17. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
18. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
19. 2 receptors. Mol. Pharmacol. 48:1995;443-450.
20. Fischer-Stenger K., Pettit D.A.D., Cabral G.A. Delta-9-tetrahydrocannabinol inhibition of tumor-necrosis-factor-alpha: Suppression of post-translational events. J. Pharmacol. Exp. Ther. 267:1993;1558-1565.
21. Fragkakis G., Probonas K., Giannikou P., Yiannakakis N., Wenger T. The effects of anandamide (endogen cannabinoid) on prostaglandin synthesis in pregnant rat. Neuroendocrinol. Lett. 17:1995;271-279.
22. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
23. Friedman, H., Shivers, S., Klein, T.W., 1994. Drugs of abuse and the immune system. In: Dean, J., Luster, M., Munson, A., Kimber, I. (Eds.), Immunotoxicology and Immunopharmacology, 2nd ed. Raven Press, New York, NY, pp. 303-322.
24. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Lefur G., Cassellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
25. Galvederochemonteix B., Nicod L.P., Dayer J.M. Tumor necrosis factor soluble receptor 75 - The principal receptor form released by human alveolar macrophages and monocytes in the presence of interferon gamma. Am. J. Resp. Cell Mol. 14:1996;279-287.
26. Hart P.H., Hunt E.K., Bonder C.S., Watson C.J., Finlayjones J.J. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J. Immunol. 157:1996;3672-3680.
27. Hichami A., Boichot E., Germain N., Legrand A., Moodley I., Lagente V. Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur. J. Pharmacol. (Mol. Pharmacol. section). 291:1995;91-97.
28. Klein T.W., Newton C., Friedman H. Resistance to Legionella-pneumophila suppressed by the marijuana component, tetrahydrocannabinol. J. Infect. Dis. 169:1994;1177-1179.
29. Kuehl F.A. Jr., Jacob T.A., Ganley O.H., Ormond R.E., Meisinger M.A.P. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc. 79:1957;5577-5578.
30. Kusher D.I., Dawson L.O., Taylor A.C., Djeu J.Y. Effect of the psychoactive metabolite of marijuana, delta(9)-tetrahydrocannabinol (THC), on the synthesis of tumor-necrosis-factor by human large granular lymphocytes. Cell Immunol. 154:1994;99-108.
31. Levitz S.M., Tabuni A., Nong S.H., Golenbock D.T. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to cryptococcus neoformans, candida albicans, and lipopolysaccharide. Infect. Immun. 64:1996;945-951.
32. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1994;1612-1623.
33. Makriyannis A., Rapaka R.S. The molecular basis of cannabinoid activity. Life Sci. 47:1990;2173-2184.
34. Mechoulam R., Hanus L., Martin B.R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48:1994;1537-1544.
35. Morahan P.S., Klykken P.C., Smith S.H., Harris L.S., Munson A.E. Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect. Immun. 23:1979;670-674.
36. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
37. 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proc. Soc. Exp. Biol. Med. 201:1992;165-168.
38. Newton C.A., Klein T.W., Friedman H. Secondary immunity to Legionella-pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect. Immun. 62:1994;4015-4020.
39. Paria B.C., Das S.K., Dey S.K. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc. Natl. Acad. Sci. USA. 92:1995;9460-9464.
40. Perlík F., Elis F., Rašková H. Anti-inflammatory properties of N-(2-hydroxyethyl)palmitamide. Acta Physiol. Hung. 39:1971;395-400.
41. Ràskovà H., Mašek K. Nouvelles possibilités d'augmentation de la résistance non-spécifique. Thérapie. 22:1967;1241-1246.
42. Rašková H., Mašek K., Linet O. Nonspecific resistance induced by palmitoylethanolamide. Toxicon. 10:1972;485-490.
43. Rola-Pleszczynski M. Immunoregulation by leukotrienes and other lipoxygenase metabolites. Immunol. Today. 6:1985;302.
44. Skaper S.D., Buriani A., Dal Toso A., Petrelli L., Romanello S., Facci L., Leon A. The aliamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA. 93:1996;3984-3989.
45. Schwartz H., Blanco F.J., Lotz M. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte-proliferation and induces apoptosis. J. Neuroimmunol. 55:1994;107-115.
46. 9-tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci. 54:1994;1281-1289.
47. Slipetz D.M., O'Neill G.P., Favreau L., Dufresne C., Gallant M., Gareau Y., Guay D., Labelle M., Metters K.M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylate cyclase. Mol. Pharmacol. 48:1995;352-361.
48. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
49. Specter S., Lancz G., Hazelden J. Marijuana and immunity-tetrahydrocannabinol mediated inhibition of lymphocyte blastogenesis. Int. J. Immunopharmacol. 12:1990;261-267.
50. 2+-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 218:1996;113-117.
51. Thomassen M.J., Divis L.T., Fisher C.J. Regulation of human alveolar macrophage inflammatory cytokine production by interleukin-10. Clin. Immunol. Immunopathol. 80:1996;321-324.
52. Wartmann M., Campbell D., Subramanian A., Burstein S.H., Davis R.J. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359:1995;133-136.
53. Wenger T., Tóth B., Martin B.R. Effects of anandamide (endogenous cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci. 56:1995;2057-2063.
54. Wiley J., Balster R., Martin B. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276:1995;49-54.
55. Wing, D.R., Leuschner, J.T.A., Brent, G.A., Harvey, D.J., Paton, W.D.M., 1985. Quantification of in vivo membrane associated delta-9-tetrahydrocannabinol and its effect on membrane fluidity. In: Harvey, D.J. (Ed.), Proceedings of the 9th International Congress of Pharmacology 3rd Satellite Symposium on Cannabis. IRL Press, Oxford, pp. 411-418.
56. Zheng Z.-M., Specter S., Friedman H. Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int. J. Immunopharmacol. 14:1992;1445-1452.
57. Zhu W.G., Newton C., Daaka Y., Friedman H., Klein T.W. Delta(9)-tetrahydrocannabinol enhances the secretion of interleukin-1 from endotoxin-stimulated macrophages. J. Pharmacol. Exp. Ther. 270:1994;1334-1339.